6533b872fe1ef96bd12d3064
RESEARCH PRODUCT
Statins in liver disease: not only prevention of cardiovascular events
Giuseppe MontaltoRizzo ManfrediAntonio Magán-fernándezGiulio Marchesinisubject
0301 basic medicinecardiovascular riskmedicine.medical_specialtydrug safetyGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineFatty livermedicineHumansHypolipidemic AgentsHepatologybusiness.industryFatty liverhydroxymethylglutaryl-CoA reductase inhibitorGastroenterologynon-alcoholic fatty liver diseaseHepatologymedicine.diseaseHydroxymethylglutaryl-CoA Reductase Inhibitors030104 developmental biologyCardiovascular DiseasesDisease Progressionlipids (amino acids peptides and proteins)030211 gastroenterology & hepatologyHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessdescription
Statins are lipid-lowering agents and one of the most pre-scribed drugs worldwide. Their main mechanism of action –inhibition of the mevalonate pathway through an effect on hydroxy-methylglutaryl CoA reductase, thus affecting the synthesis of cholesterol in the liver – makes this class of drugs pivotal in primary and secondary prevention of cardio-vascular risk, as extensively demonstrated in large prospective, randomized controlled trials. Along the years, we learned that the lower the better, and LDL-cholesterol targets have been progressively reduced to values ≤70 mg/dL for secondary prevention or in the presence of diabetes.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-01-01 |